此外，一批处于IPO关键阶段的企业掌舵者同台获誉，进一步凸显湖南民营经济梯队培育的良好成效。 其中，英氏控股董事长马文斌上榜，该公司北交所IPO已顺利过会；美程新材料董事长方豪杰获评，企 业已于2025年启动上市辅导，IPO进程稳步推进。 此次表彰的百名优秀民营企业家，覆盖湖南工程机械、绿色农产品及食品加工、生物医药、新能源、先 进材料等重点产业链，既是湖南传统产业转型升级、优势产业延链强链的引领者，也是新兴产业培育、 新质生产力打造的开拓者，成为该省建设"4×4"现代化产业体系、实现"三高四新"发展目标的重要支 撑。 从获评名单来看，三一重工（600031）、蓝思科技（300433）、爱尔眼科（300015）、盐津铺子 （002847）、金杯电工（002533）、楚天科技（300358）、达嘉维康（301126）、军信股份 （301109）、圣湘生物、万兴科技（300624）等多家湘股的董事长/核心掌舵人悉数上榜，覆盖工程机 械、消费制造、医药生物、新能源科技等多个优势产业领域，成为湖南实体经济与资本市场融合发展的 中坚力量。 多个上市湘企关联企业负责人也获此殊荣。克明食品（002661）全资子公司克明五谷 ...

Core Viewpoint - The AI medical sector experienced a decline of 0.66% on February 11, with QianYuan Pharmaceutical leading the drop. The Shanghai Composite Index rose by 0.09%, while the Shenzhen Component Index fell by 0.35% [1]. Group 1: Market Performance - The closing price of QianYuan Pharmaceutical was 11.44, down by 4.67%, with a trading volume of 209,800 shares and a transaction value of 243 million [2]. - The AI medical sector saw a net outflow of 1.345 billion from major funds, while retail investors contributed a net inflow of 1.14 billion [2][3]. Group 2: Individual Stock Performance - YoukeDe (688158) closed at 37.54, up by 5.12%, with a trading volume of 631,000 shares and a transaction value of 2.36 billion [1]. - AidiTe (301580) closed at 55.18, up by 4.63%, with a trading volume of 46,100 shares and a transaction value of 251 million [1]. - SanNuo Biology (300298) closed at 18.54, up by 2.71%, with a trading volume of 105,200 shares and a transaction value of 194 million [1]. - The top decliners included QianYuan Pharmaceutical (300254) and KaiPu Biology (300639), with declines of 4.67% and 4.23%, respectively [2].

登录新浪财经APP 搜索【信披】查看更多考评等级 1.案件所处的诉讼阶段：一审法院已立案受理，案号为(2026)京0108民初2924号，案由为买卖合同纠纷 案，本案暂未开庭审理。 2.上市公司下属控股子公司所处的当事人地位：原告。 3.涉案的金额：合同款人民币2,000万元、资金占用损失（含违约责任）；及相关律师费、保全费、保全 担保费、诉讼费等全部费用。 4.对上市公司损益产生的影响：目前该案件尚未判决，公司尚无法判断最终诉讼结果。最终结果对公司 本期利润或期后利润的影响尚存在不确定性。 一、本次重大诉讼受理的基本情况 古汉医药集团股份公司（以下简称"公司"）下属控股子公司湖南启迪药业生物有限公司（以下简称"原 告"、"子公司"）向北京市海淀区人民法院递交民事起诉状，起诉宁波医多多电子商务有限公司退还合 同款，同时诉福州市乐拓企业管理有限公司、北京涂多多电子商务股份有限公司依法承担连带责任，北 京市海淀区人民法院已受理本案，现对本案情况予以公告。 被告三：北京涂多多电子商务股份有限公司 （二）本案基本情况 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚假记载、误导性陈述或重大遗 漏。 重 ...

登录新浪财经APP 搜索【信披】查看更多考评等级 证券代码：000590 证券简称：古汉医药 公告编号：2026-004 古汉医药集团股份公司 关于控股子公司重大诉讼的公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚假记载、误导性陈述或重大遗 漏。 重要内容提示： 1.案件所处的诉讼阶段：一审法院已立案受理，案号为(2026)京0108民初2924号，案由为买卖合同纠纷 案，本案暂未开庭审理。 2.上市公司下属控股子公司所处的当事人地位：原告。 3.涉案的金额：合同款人民币2,000万元、资金占用损失（含违约责任）；及相关律师费、保全费、保全 担保费、诉讼费等全部费用。 4.对上市公司损益产生的影响：目前该案件尚未判决，公司尚无法判断最终诉讼结果。最终结果对公司 本期利润或期后利润的影响尚存在不确定性。 一、本次重大诉讼受理的基本情况 古汉医药集团股份公司（以下简称"公司"）下属控股子公司湖南启迪药业生物有限公司（以下简称"原 告"、"子公司"）向北京市海淀区人民法院递交民事起诉状，起诉宁波医多多电子商务有限公司退还合 同款，同时诉福州市乐拓企业管理有限公司、北京涂多多电子商务股份有限公 ...

证券代码：000590 证券简称：古汉医药 公告编号：2026-004 古汉医药集团股份公司 关于控股子公司重大诉讼的公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚假 假记载、误导性陈述或重大遗漏。 记载、误导性陈述或重大遗漏。 重要内容提示： 1.案件所处的诉讼阶段：一审法院已立案受理，案号为(2026)京 0108 民初 2924 号，案由为买卖合同纠纷案，本案暂未开庭审理。 2.上市公司下属控股子公司所处的当事人地位：原告。 3.涉案的金额：合同款人民币 2,000 万元、资金占用损失（含违约责任）； 及相关律师费、保全费、保全担保费、诉讼费等全部费用。 二、有关本案的基本情况 （一）诉讼各方当事人 原告：湖南启迪药业生物有限公司 被告一：宁波医多多电子商务有限公司 被告二：福州市乐拓企业管理有限公司 被告三：北京涂多多电子商务股份有限公司 4.对上市公司损益产生的影响：目前该案件尚未判决，公司尚无法判断最终 诉讼结果。最终结果对公司本期利润或期后利润的影响尚存在不确定性。 一、本次重大诉讼受理的基本情况 古汉医药 ...

Regulatory Environment - The capital market is experiencing a wave of intensive and strict regulatory actions, establishing a rapid response chain from investigation to punishment [1][16] - As of February 5, 2026, at least six listed companies or key individuals have been investigated, averaging one case every six days, with 13 companies receiving administrative penalty notices, averaging less than three days between each [1][10] Investigation and Penalties - Companies such as Qingyue Technology and Yuandao Communication have had their accounts frozen due to suspected information disclosure violations, with Qingyue's frozen accounts totaling approximately 134 million yuan and Yuandao's around 9.04 million yuan [2][17] - The investigation into these companies is ongoing, with significant risks of forced delisting if found guilty of major violations [5][19] Financial Performance - Qingyue Technology anticipates a net loss of between 74 million and 110 million yuan for the year 2025, attributed to intensified competition and price pressures in the electronic paper module market [3][18] - Yuandao Communication expects a substantial decline in net profit for 2025, projected to drop by 64.59% to 76.39% year-on-year [4][19] Types of Violations - The reasons for recent investigations have diversified beyond typical information disclosure violations, including market manipulation and misleading statements [6][21] - Specific cases highlight the regulatory focus on misleading statements and significant omissions, indicating a more granular approach to enforcement [8][23] Frequency of Penalties - Since the beginning of 2026, 10 listed or delisted companies have received administrative penalties, with an additional three receiving notices of intended penalties, indicating a high frequency of enforcement actions [10][24] - The issues identified among these companies include systemic financial fraud and misuse of company funds, which have been a focus of regulatory scrutiny [11][25] Long-term Regulatory Mechanisms - The regulatory framework aims to establish a long-term mechanism that discourages violations through comprehensive accountability and technological empowerment [13][28] - The integration of big data and AI in regulatory practices enhances the precision and effectiveness of oversight, targeting deeper issues within corporate governance [14][28]

Core Viewpoint - The recent regulatory actions in the capital market indicate a "zero tolerance" approach, establishing a new normal for comprehensive supervision that aims to enhance the quality of listed companies and purify the market ecosystem [1][15]. Regulatory Actions - Since the beginning of 2026, at least six listed companies or key individuals have been investigated, averaging one case every six days, with 13 companies receiving administrative penalty notices or prior notifications, averaging less than three days between each [1][11]. - The regulatory focus has shifted from merely punishing companies to targeting the entire ecosystem involved in fraudulent activities, emphasizing the need for a comprehensive response chain from investigation to punishment [1][14]. Types of Violations - The reasons for investigations have diversified, including market manipulation, information disclosure violations, misleading statements, and significant omissions [8][9]. - Specific cases highlight the increasing granularity of regulatory scrutiny, with investigations targeting misleading statements and significant omissions in disclosures [9]. Financial Penalties - As of February 5, 2026, ten listed companies or delisted companies have received administrative penalties, with three others receiving prior notifications, indicating a high frequency of enforcement actions [11]. - Serious cases of systemic financial fraud, such as *ST Changyao, have led to severe penalties, including forced delisting and substantial fines [11]. Impact on Companies - Companies like Qingyue Technology and Yuandao Communication face significant operational pressures alongside regulatory scrutiny, with projected losses and substantial declines in net profits [4][5][6]. - The regulatory environment has prompted a reduction in the misuse of company funds, with many previously problematic shareholders returning misappropriated funds [12]. Long-term Mechanism - The regulatory framework aims to establish a long-term mechanism that discourages violations through strict enforcement and technological empowerment, ensuring that companies adhere to compliance standards [13][15]. - The integration of advanced technologies like big data and AI into regulatory practices enhances the precision and effectiveness of oversight, targeting deeper and more complex fraudulent behaviors [14].

伴随2025年业绩预告密集发布，一批上市公司拉响退市风险"警报"。 据上海证券报初步统计，近期，已有*ST观典、*ST岩石、*ST精伦、*ST春天等多家*ST公司发布公 告，提示投资者关注退市风险。其中，*ST岩石、*ST精伦已明确触及财务类退市指标，预计2025年年 报披露后终止上市。*ST太和等公司的财务指标则暂时"踩线达标"，但会计师均不能确定其2025年扣除 后的营业收入超过3亿元，仍存在退市风险隐患。 业内人士认为，自退市新规发布实施以来，市场对绩差公司的出清力度持续加大。在监管层持续强化常 态化退市机制的背景下，进退有序、及时出清的格局正加速形成。 多家*ST公司退市风险高悬 记者注意到，退市新规收紧了财务类退市指标，将主板亏损公司的营业收入指标从1亿元调高至3亿元， 进一步加大"壳公司"出清力度。在此背景下，一批2025年业绩预期不佳的*ST公司，面临触发组合类财 务退市指标的风险，"保壳"压力陡增。 以*ST岩石、*ST精伦为例，据其披露的2025年业绩预告，两家公司收入均不足3亿元且利润亏损，触及 组合类财务退市指标，拉响退市风险"警报"。 以*ST熊猫为例，公司年审会计师出具专项说明表示非 ...

Group 1 - The company forecasts a net profit loss for the fiscal year 2025, covering the period from January 1, 2025, to December 31, 2025 [1][2] - The financial data related to this earnings forecast has not been audited by the accounting firm, but preliminary communication indicates no significant disagreements between the company and the auditors [2][3] Group 2 - The main reasons for the expected loss include a slight decline in overall gross profit due to industry policy impacts and rising costs of raw material procurement [3] - The company has conducted impairment testing on goodwill and related asset groups from the acquisition of Guangdong Xiantong, leading to the recognition of impairment provisions [3] - The company has also made provisions for credit impairment on receivables based on actual operating conditions and relevant accounting policies [3]

格隆汇1月29日丨古汉医药(000590.SZ)发布2025年度业绩预告，报告期内，归属于上市公司股东的净利 润为亏损4,500万元—5,500万元，上年同期亏损1.25亿元；扣除非经常性损益后的净利润为亏损5,500万 元—6,500万元，上年同期亏损1.70亿元。 ...